These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 35581005)
21. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies. Sahloul O; Louapre C; Beigneux Y; Lubetzki C; Maillart E; Roux T Mult Scler Relat Disord; 2024 May; 85():105557. PubMed ID: 38520946 [TBL] [Abstract][Full Text] [Related]
22. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Zhu C; Zhou Z; Roos I; Merlo D; Kalincik T; Ozakbas S; Skibina O; Kuhle J; Hodgkinson S; Boz C; Alroughani R; Lechner-Scott J; Barnett M; Izquierdo G; Prat A; Horakova D; Kubala Havrdova E; Macdonell R; Patti F; Khoury SJ; Slee M; Karabudak R; Onofrj M; Van Pesch V; Prevost J; Monif M; Jokubaitis V; van der Walt A; Butzkueven H; J Neurol Neurosurg Psychiatry; 2022 Dec; 93(12):1330-1337. PubMed ID: 36261289 [TBL] [Abstract][Full Text] [Related]
23. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA; Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593 [TBL] [Abstract][Full Text] [Related]
24. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. Roy R; Alotaibi AA; Freedman MS CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705 [TBL] [Abstract][Full Text] [Related]
25. Fingolimod reduces the clinical expression of active demyelinating lesions in MS. Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094 [TBL] [Abstract][Full Text] [Related]
26. Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes. Gulec B; Everest E; Gorkey OD; Koc M; Tutuncu M; Saip S; Siva A; Uygunoglu U Eur J Neurol; 2023 Sep; 30(9):2745-2751. PubMed ID: 37300847 [TBL] [Abstract][Full Text] [Related]
27. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients. Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413 [TBL] [Abstract][Full Text] [Related]
28. Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months. Tichá V; Počíková Z; Vytlačil J; Štěpánová R BMC Neurol; 2022 Apr; 22(1):143. PubMed ID: 35428205 [TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484 [TBL] [Abstract][Full Text] [Related]
30. Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis. Bajrami A; Tamanti A; Peloso A; Ziccardi S; Guandalini M; Calderone M; Castellaro M; Pizzini FB; Montemezzi S; Marastoni D; Calabrese M J Neurol; 2024 May; 271(5):2149-2158. PubMed ID: 38289534 [TBL] [Abstract][Full Text] [Related]
31. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla AA; Karkare SU; McGuiness CB; Korn JR PLoS One; 2014; 9(2):e88472. PubMed ID: 24516663 [TBL] [Abstract][Full Text] [Related]
32. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498 [TBL] [Abstract][Full Text] [Related]
33. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives. Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L Cells; 2022 Jun; 11(13):. PubMed ID: 35805142 [TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497 [TBL] [Abstract][Full Text] [Related]
36. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R; CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772 [TBL] [Abstract][Full Text] [Related]
37. Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes Hunter SF; Thomas FP; Cascione M; Williams IM; Meng X; Schofield L; Weiss JL; Tenenbaum N; Cree BAC; Mult Scler Relat Disord; 2020 Oct; 45():102346. PubMed ID: 32717684 [TBL] [Abstract][Full Text] [Related]
38. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA). Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799 [TBL] [Abstract][Full Text] [Related]
39. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS). Meissner A; Limmroth V Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870 [TBL] [Abstract][Full Text] [Related]